Pharmacological manipulation of oxytocin receptor signaling during mouse embryonic development results in sex-specific behavioral effects in adulthood

Disruptions of the oxytocin system impair sociability and cognitive flexibility in a subchronic phencyclidine model of schizophrenia

Previous research suggests that the oxytocin (Oxt) system may play a role in the etiology of schizophrenia. To investigate, we used a subchronic phencyclidine (PCP) mouse model to test how disruption of Oxt or the Oxt receptor (Oxtr) affects schizophrenia-related behaviors. Specifically, we assessed how subchronic PCP impacted hyperlocomotion, sociability, and passive stress coping in male Oxt and Oxtr knockout (-/-) and wildtype (+/+) mice. Additionally, we evaluated immediate early gene activation in Oxtr -/- and +/+ mice to identify brain regions where the Oxt system might impact schizophrenia-associated behaviors. Lastly, we investigated cognitive flexibility in Oxtr -/- and +/+ mice. We found that subchronic PCP treatment decreased social interactions in Oxt -/- mice as compared to Oxt +/+ mice, with no genotypic differences in the Oxtr line of mice. Increased c-Fos expression was observed in Oxtr -/- mice relative to Oxtr +/+ controls in the medial amygdala and the paraventricular nucleus of the hypothalamus following a forced swim test. Finally, we found deficits in cognitive flexibility in Oxtr -/- mice treated with PCP, relative to Oxtr +/+ mice. These findings are consistent with the hypothesis that Oxt may buffer against some of the schizophrenia-associated symptoms induced by subchronic PCP treatment. Based on the data, we speculate that compensatory mechanisms may be able to accommodate the loss of the Oxt system, depending on the origin of the dysfunction and the behavioral endpoint in question. These findings also add support to data linking disruption of Oxt system signaling to schizophrenia.

Role of Brain Modulators in Neurodevelopment: Focus on Autism Spectrum Disorder and Associated Comorbidities

Autism spectrum disorder (ASD) and associated neurodevelopmental disorders share similar pathogenesis and clinical features. Pathophysiological changes in these diseases are rooted in early neuronal stem cells in the uterus. Several genetic and environmental factors potentially perturb neurogenesis and synaptogenesis processes causing incomplete or altered maturation of the brain that precedes the symptomology later in life. In this review, the impact of several endogenous neuromodulators and pharmacological agents on the foetus during pregnancy, manifested on numerous aspects of neurodevelopment is discussed. Within this context, some possible insults that may alter these modulators and therefore alter their role in neurodevelopment are high-lighted. Sometimes, a particular insult could influence several neuromodulator systems as is supported by recent research in the field of ASD and associated disorders. Dopaminergic hy-pothesis prevailed on the table for discussion of the pathogenesis of schizophrenia (SCH), atten-tion-deficit hyperactivity disorder (ADHD) and ASD for a long time. However, recent cumulative evidence suggests otherwise. Indeed, the neuromodulators that are dysregulated in ASD and comorbid disorders are as diverse as the causes and symptoms of this disease. Additionally, these neuromodulators have roles in brain development, further complicating their involvement in comorbidity. This review will survey the current understanding of the neuromodulating systems to serve the pharmacological field during pregnancy and to minimize drug-related insults in pa-tients with ASD and associated comorbidity disorders, e.g., SCH or ADHD.

The oxytocin system and early-life experience-dependent plastic changes

Early-life experience influences social and emotional behaviour in adulthood. Affiliative tactile stimuli in early life facilitate the development of social and emotional behaviour, whereas early-life adverse stimuli have been shown to increase the risk of various diseases in later life. On the other hand, oxytocin has been shown to have organizational actions during early-life stages. However, the detailed mechanisms of the effects of early-life experience and oxytocin remain unclear. Here, we review the effects of affiliative tactile stimuli during the neonatal period and neonatal oxytocin treatment on the activity of the oxytocin-oxytocin receptor system and social or emotional behaviour in adulthood. Both affiliative tactile stimuli and early-life adverse stimuli in the neonatal period acutely activate the oxytocin-oxytocin receptor system in the brain but modulate social behaviour and anxiety-related behaviour apparently in an opposite direction in adulthood. Accumulating evidence suggests that affiliative tactile stimuli and exogenous application of oxytocin in early-life stages induce higher activity of the oxytocin-oxytocin receptor system in adulthood, although the effects are dependent on experimental procedures, sex, dosages and brain regions examined. On the other hand, early-life stressful stimuli appear to induce reduced activity of the oxytocin-oxytocin receptor system, possibly leading to adverse actions in adulthood. It is possible that activation of a specific oxytocin system can induce beneficial actions against early-life maltreatments and thus could be used for the treatment of developmental psychiatric disorders.